Study Title and Description
A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study).
Key Questions Addressed
|3||In adult renal transplants, how do immunosuppressive regimens designed to reduce or eliminate exposure to CNI toxicity compare with each other and with full-dose CNI regimens for health outcomes? AND How does the type of induction agent (including when no induction is used) and the use of concurrent immunosuppressive agents affect outcomes of regimens that reduce or eliminate CNI exposure?|
Primary Publication Information
|Title||A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study).|
|Author||Durrbach A., Pestana JM., Pearson T., Vincenti F., Garcia VD., Campistol J., Rial Mdel C., Florman S., Block A., Di Russo G., Xing J., Garg P., Grinyó J.|
|Country||Bicêtre Hospital, Kremlin Bicêtre, IFRNT, Université Paris sud, France. email@example.com|
Pubmed ID: 20415898
Secondary Publication Information
There are currently no secondary publications defined for this study.
Extraction Form: Comparative Effectiveness of Regimens
Results & Comparisons
No Results found.